hUMSC vs. hUMSC–Exosome: Which One Is Better for Epilepsy?

Hastuti, Sri; Idroes, Rinaldi; Imran, Imran; Ramli, Yetty; Abas, Abdul Hawil; Tallei, Trina Ekawati

doi:10.3390/ph15101247

Cited by 3 publications

(1 citation statement)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EVs naturally secreted from stem cells (e.g., NSCs, induced pluripotent stem cells (iPSCs), and mesenchymal stem cells (MSCs)) have diverse therapeutic properties, including anti-inflammation, immunity modulation, and tissue repair [25]. Furthermore, stem cell-derived EVs can be more easily isolated and preserved, have higher safety and immune tolerance, and present fewer ethical issues when compared to the full cell product [26], [23]. While NSC-derived EV therapeutics have been studied for treating neurodegeneration and cancer, studies on EVs derived from iNSCs for brain cancer therapy have not yet been reported [27], [28], [29].…”

Section: Introductionmentioning

confidence: 99%

Auto-loaded TRAIL-exosomes derived from induced neural stem cells for brain cancer therapy

Zhang,

Taylor,

Valdivia

et al. 2024

Preprint

View full text Add to dashboard Cite

Transdifferentiation (TD), a somatic cell reprogramming process that eliminates pluripotent intermediates, creates cells that are ideal for personalized anti-cancer therapy. Here, we provide the first evidence that extracellular vesicles (EVs) from TD-derived induced neural stem cells (Exo-iNSCs) are an efficacious treatment strategy for brain cancer. We found that genetically engineered iNSCs generated EVs loaded with the tumoricidal gene product TRAIL at nearly twice the rate as their parental fibroblasts, and the TRAIL produced by iNSCs were naturally loaded into the lumen of EVs and arrayed across their outer membrane (Exo-iNSC-TRAIL). Uptake studies in ex vivo organotypic brain slice cultures showed Exo-iNSC-TRAIL selectively accumulates within tumor foci, and co-culture assays showed that Exo-iNSC-TRAIL killed metastatic and primary brain cancer cells more effectively than free TRAIL. In an orthotopic mouse model of brain cancer, Exo-iNSC-TRAIL reduced breast-to-brain tumor xenografts around 3000-fold greater than treatment with free TRAIL, with all Exo-iNSC-TRAIL treated animals surviving through 90 days post-treatment. In additional in vivo testing against aggressive U87 and invasive GBM8 glioblastoma tumors, Exo-iNSC-TRAIL also induced a statistically significant increase in survival. These studies establish a new easily generated, stable, tumor-targeted EV to efficaciously treat multiple forms of brain cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Auto-loaded TRAIL-exosomes derived from induced neural stem cells for brain cancer therapy

Zhang,

Taylor,

Valdivia

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

Plasma exosomes proteome profiling discovers protein markers associated with the therapeutic effect of Chaihu-Longgu-Muli decoction on temporal lobe epilepsy

Yang

Huang

Zhu

et al. 2024

Journal of Ethnopharmacology

View full text Add to dashboard Cite

Clinical applications of stem cell-derived exosomes

Tan,

Li,

Wang

et al. 2024

Sig Transduct Target Ther

View full text Add to dashboard Cite

Although stem cell-based therapy has demonstrated considerable potential to manage certain diseases more successfully than conventional surgery, it nevertheless comes with inescapable drawbacks that might limit its clinical translation. Compared to stem cells, stem cell-derived exosomes possess numerous advantages, such as non-immunogenicity, non-infusion toxicity, easy access, effortless preservation, and freedom from tumorigenic potential and ethical issues. Exosomes can inherit similar therapeutic effects from their parental cells such as embryonic stem cells and adult stem cells through vertical delivery of their pluripotency or multipotency. After a thorough search and meticulous dissection of relevant literature from the last five years, we present this comprehensive, up-to-date, specialty-specific and disease-oriented review to highlight the surgical application and potential of stem cell-derived exosomes. Exosomes derived from stem cells (e.g., embryonic, induced pluripotent, hematopoietic, mesenchymal, neural, and endothelial stem cells) are capable of treating numerous diseases encountered in orthopedic surgery, neurosurgery, plastic surgery, general surgery, cardiothoracic surgery, urology, head and neck surgery, ophthalmology, and obstetrics and gynecology. The diverse therapeutic effects of stem cells-derived exosomes are a hierarchical translation through tissue-specific responses, and cell-specific molecular signaling pathways. In this review, we highlight stem cell-derived exosomes as a viable and potent alternative to stem cell-based therapy in managing various surgical conditions. We recommend that future research combines wisdoms from surgeons, nanomedicine practitioners, and stem cell researchers in this relevant and intriguing research area.

show abstract

hUMSC vs. hUMSC–Exosome: Which One Is Better for Epilepsy?

Cited by 3 publications

References 83 publications

Auto-loaded TRAIL-exosomes derived from induced neural stem cells for brain cancer therapy

Auto-loaded TRAIL-exosomes derived from induced neural stem cells for brain cancer therapy

Plasma exosomes proteome profiling discovers protein markers associated with the therapeutic effect of Chaihu-Longgu-Muli decoction on temporal lobe epilepsy

Clinical applications of stem cell-derived exosomes

Contact Info

Product

Resources

About